Barely Significant
← all excerpts

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.

Eur Urol Open Sci · 2022 · PMC9142735 · PMID 35638086

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
Take Home Message Intratumoral injection of ilixadencel, consisting of proinflammatory allogeneic dendritic cells, before nephrectomy, followed by sunitinib treatment after nephrectomy showed a trend for improved tumor response rate and overall survival, compared with sunitinib monotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.